Chien-Cheng Lai1, Tzu-Ju Chen2,3,4, Ti-Chun Chan4,5, Wan-Shan Li2,3,4, Hong-Lin He2,6,7. 1. College of Medicine, Chang Gung University, Taoyuan 333323, Taiwan. 2. Department of Pathology, Chi Mei Medical Center, Tainan 71004, Taiwan. 3. Department of Medical Technology, Chung Hwa University of Medical Technology, Tainan 71703, Taiwan. 4. Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung 804201, Taiwan. 5. National Institute of Cancer Research, National Health Research Institutes, Tainan 704016, Taiwan. 6. Department of Optometry, Chung Hwa University of Medical Technology, Tainan 71703, Taiwan. 7. Department of Pathology, E-DA Hospital & E-DA Cancer Hospital, I-Shou University, Kaohsiung 82445, Taiwan.
Abstract
Background: Bioinformatic analysis has revealed that OXR1 is significantly downregulated in muscle-invasive bladder cancer. Patients & methods: The expression of OXR1 in patients with urothelial carcinoma was evaluated by immunohistochemistry, including 340 cases with urothelial carcinoma in the upper urinary tract and 295 in the urinary bladder. Results: Low expression of OXR1 was significantly correlated with adverse pathological parameters including high primary tumor (pT) stage, high node stage, high histological grade, high mitotic activity and increased vascular or perineural invasion (all p < 0.05). Low expression of OXR1 independently predicted worse metastasis-free survival (p = 0.033) in urothelial carcinoma of the upper urinary tract and worse disease-specific survival (p = 0.022) and metastasis-free survival (p < 0.001) in urothelial carcinoma of the urinary bladder. Conclusion: Low expression of OXR1 is an adverse prognostic factor in urothelial carcinoma.
Background: Bioinformatic analysis has revealed that OXR1 is significantly downregulated in muscle-invasive bladder cancer. Patients & methods: The expression of OXR1 in patients with urothelial carcinoma was evaluated by immunohistochemistry, including 340 cases with urothelial carcinoma in the upper urinary tract and 295 in the urinary bladder. Results: Low expression of OXR1 was significantly correlated with adverse pathological parameters including high primary tumor (pT) stage, high node stage, high histological grade, high mitotic activity and increased vascular or perineural invasion (all p < 0.05). Low expression of OXR1 independently predicted worse metastasis-free survival (p = 0.033) in urothelial carcinoma of the upper urinary tract and worse disease-specific survival (p = 0.022) and metastasis-free survival (p < 0.001) in urothelial carcinoma of the urinary bladder. Conclusion: Low expression of OXR1 is an adverse prognostic factor in urothelial carcinoma.